Nyrada (ASX:NYR) has announced positive results from a preclinical rat study evaluating the efficacy of its lead drug candidate, NYR-BI03, in coronary heart disease. …
Nyrada’s says lead drug candidate demonstrates significant cardioprotection
October 1, 2024 Latest NewsAustralian Biotech
Latest Video
New Stories
-
Medicines Australia strikes cautious tone on HTA review implementation group
October 2, 2024 - - Latest News -
AbbVie heads the list of Australia's best workplaces in pharma and biotech
October 2, 2024 - - Latest News -
Sigma offers court-enforceable undertaking in response to ACCC concerns
October 2, 2024 - - Latest News -
Pfizer renews commitment to all patients during fourth annual patient week
October 2, 2024 - - Latest News -
Australian company Vaxxas receives significant investment from Endpoints Capital
October 1, 2024 - - Australian Biotech -
Cartherics raises over $15 million in private financing round
October 1, 2024 - - Australian Biotech -
Nyrada’s says lead drug candidate demonstrates significant cardioprotection
October 1, 2024 - - Latest News